CLINICAL APPROACH AND GUIDELINES FOR MANAGEMENT OF SEPSIS ASSOCIATED ENCEPHALOPATHY

Ayu Trisnawati, Badrul Munir
  MNJ, pp. 98-104  

Abstract


Septic associated encephalopathy (SAE) is simply define as an encephalopathy incidence that occurs in sepsis patients. Ironically this entity can increases the mortality rate. Importantly, the clinical presentations of this entity is vary ranging from malaise to coma condition. The central nervous system is susceptible to damage that caused by systemic inflammation including sepsis with complex pathophysiologies such as endothelial dysfunction, neurotransmitter imbalance, oxidative stress, mitochondrial dysfunction and apoptosis. In general, current management of SAE is similar with the management of sepsis incidence which includes infections management, maintaining tissue perfusion and symptomatic therapy to treat delirium and convulsions that may occur. Also, several studies continue to be developed including the use of corticosteroids, magnesium, antioxidants, and immunoglobulin. Early identification and appropriate initial handling significantly affect the output of the SAE patients.


Keywords


Sepsis Associated Encephalopathy; septic condition; brain in sepsis

Full Text:

PDF

References


Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. Springer Berlin Heidelberg; 2017.34:304. DOI: 10.1007/s00134-017-4683-6

Sunarti S, Rahayu M, Desetyaputra DR. Geriatric patient with delirium profile in saiful anwar general hospital malang from january 2005 until june 2010. Malang Neurology Journal; 2015.1:61–7. DOI: http://dx.doi.org/10.21776/ub.mnj.2015.001.02.3

Sankowski R, Mader S, Valdés-ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci; 2015.9:1–20. DOI: 10.3389/fncel.2015.00028

Zampieri FG, Park M, Machado FS, Azevedo LC. Sepsis-associated encephalopathy: not just delirium. Clinics (Sao Paulo); 2011.66(10):1825-31. DOI: 10.1590/S1807-59322011001000024

Chaudhry N, Duggal AK. Sepsis Associated Encephalopathy. Adv Med Hindawi Publ Corp. 2014

Ropper AH, Samuels MA, Klein JP. Adams and Victor’s Principles of Neurology. 10th ed. McGrawHill Education; 2014

Albert D, Block AM, Bruce BB, E.Haines D, McCloskey LJ, Mitchell RN, et al. Dorland’s illustrated medical dictionary. 32nd ed. Philadelphia: Elsevier Saunders; 2012

Zhang Q, Sheng Z, Yao Y. Septic encephalopathy: when cytokines interact with acetylcholine in the brain. Mil Med Res. 2014;1(20):1–9. DOI: 10.1186/2054-9369-1-20

Heming N, Mazeraud A, Verdonk F, Bozza FA, Chrétien F, Sharshar T. Neuroanatomy of sepsisassociated encephalopathy. Critical Care; 2017.21:26. DOI: 10.1186/s13054-017-1643-z

Opal SM. Endotoxins and other sepsis triggers. Karger; 2010.167:14-24. DOI: 10.1159/000315915

Brown L, Wolf JM, Prados-rosales R, Casadevall A. Through the wall: extracellular vesicles in Grampositive bacteria, mycobacteria and fungi. Nat Publ Gr. Nature Publishing Group; 2015.(September). DOI: 10.1038/nrmicro3480

Sweis R, Ortiz J, Biller J. Neurology of sepsis. Curr Neurol Neurosci Rep; 2016.16(21):1–10. DOI: 10.1007/s11910-016-0623-z

Sonneville R, Verdonk F, Rauturier C, Klein IF, Wolff M, Annane D. Understanding brain dysfunction in sepsis. Ann Intensive Care; 2013.3(15):1–11. DOI: 10.1186/2110-5820-3-15

Dal-Pizzol, Felipe, Tomasi, Cristiane D, Ritter, Cristiane. Septic encephalopathy: does inflammation drive the brain crazy? Brazilian Journal of Psychiatry; Epub June 11, 2014.36(3), 251-258. DOI: 10.1590/1516-4446-2013-1233

Hodes GE, Kana V, Menard C, Merad M, Russo SJ. Neuroimmune mechanisms of depression. Nat Neurosci; 2015.18(10). DOI: 10.1038/nn.4113

Kanczkowski W, Sue M, Bornstein SR. Adrenal Gland Microenvironment and its involvement in the regulation of stress-induced hormone secretion during sepsis. Front. Endocrinol; 2016. 7:156. DOI: 10.3389/fendo.2016.00156

Garzoni L, Faure C, Frasch MG. Fetal cholinergic anti-inflammatory pathway and necrotizing enterocolitis: the brain-gut connection begins in utero. Front Integr Neurosci; 2013.7(August):1–9. DOI: 10.3389/fnint.2013.00057

Poujade J, Sonneville R, Souweine B, Azoulay E, Darmon M, Mariotte E, et al. Determinants and prognostic value of sepsis- associated encephalopathy: insights from the prospective multicentre outcomerea registry. Intensive Care Med Exp; 2015.3(Suppl 1):1–2. DOI: 10.1186/2197-425X-3-S1-A48.

Zenaide PV, Gusmao-Flores D. Biomarkers in septic encephalopathy: a systematic review of clinical studies. Rev Bras Ter Intensiva; 2013.25(1):56–62. PMC4031860

Fink MP, Warren HS. Strategies to improve drug development for sepsis. Nat Publ Gr. Nature Publishing Group; 2014. DOI: 10.1038/nrd4368

Witt KA, Sandoval KE. Steroids and the blood – brain barrier: therapeutic implications. 1st ed. vol. 71, pharmacology of the blood brain barrier: targeting cns disorders. Elsevier Inc; 2014. P. 361-390. DOI: 10.1016/bs.apha.2014.06.018

Annane D. Corticosteroids for severe sepsis: an evidence- based guide for physicians. Ann Intensive Care. Springer Open Ltd; 2011.1(1):7. DOI: 10.1186/2110-5820-1-7

Galley HF. Bench-to-bedside review: Targeting antioxidants to mitochondria in sepsis. Gall Crit Care; 2010.14(230). DOI: 10.1186/cc9098

Chelkeba L, Ahmadi A, Abdollahi M, Najafi A, Ghadimi MH. The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial. Ann Intensive Care. Springer Paris; 2015.5(29). DOI: 10.1186/s13613-015-0071-y

Opal SM, Francois B, Larosa SP, Angus DC, Schein R, Lynn M, et al. Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis. J Am Med Assoc; 2015.309(11). DOI: 10.1001/jama.2013.2194

Bermejo-martin JF, Giamarellos-bourboulis EJ. International journal of antimicrobial agents endogenous immunoglobulins and sepsis: new perspectives for guiding replacement therapies. Int J Antimicrob Agents. Elsevier BV; 2015.46. DOI: 10.1016/j.ijantimicag.2015

Shankar-hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care; 2012.16(206). DOI: 10.1186/cc10597

Marissa A, Mad L, Leinolla D, Jb MIII. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock (Review). Cochrane Database Syst Rev; 2013.(9). DOI: 10.1002/14651858.CD001090.pub2

Hamano N, Nishi K, Onose A, Okamoto A, Umegaki T, Yamazaki E, et al. Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock. J Intensive Care; 2013.1(4):2–3. DOI: 10.1186/2052-0492-1-4

Oda S, Aibiki M, Ikeda T, Imaizumi H, Endo S, Ochiai R, et al. The Japanese guidelines for the management of sepsis. J Intensive Care; 2014.2(55). DOI: 10.1186/s40560-014-0055-2

Semmler A, Widmann C N, Okulla T, Urbach H, Kaiser M, Widman G, et al. Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. Journal of Neurology, Neurosurgery & Psychiatry; 2013.Jan;84(1):62-9. DOI: 10.1136/jnnp-2012-302883

Khan J, Harrison TB, Rich MM. Mechanisms of neuromuscular dysfunction in critical illness. Crit Care Clin; 2009.24(1) DOI: 10.1016/j.ccc.2007.10.004

Zhou C, Wu L, Ni F, Ji W, Wu J, Zhang H. Critical illness polyneuropathy and myopathy: a systematic review. Neural Regen Res; 2014.9(1):101–10. DOI: 10.4103/1673-5374.125337


Refbacks

  • There are currently no refbacks.